WO1995011243A1 - Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d - Google Patents

Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d Download PDF

Info

Publication number
WO1995011243A1
WO1995011243A1 PCT/EP1994/003387 EP9403387W WO9511243A1 WO 1995011243 A1 WO1995011243 A1 WO 1995011243A1 EP 9403387 W EP9403387 W EP 9403387W WO 9511243 A1 WO9511243 A1 WO 9511243A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
methyl
compound
dihydro
methylpiperazin
Prior art date
Application number
PCT/EP1994/003387
Other languages
English (en)
Inventor
Graham Francis Joiner
Laramie Mary Gaster
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939321490A external-priority patent/GB9321490D0/en
Priority claimed from GB939325866A external-priority patent/GB9325866D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to EP94930171A priority Critical patent/EP0724580A1/fr
Priority to JP7511300A priority patent/JPH09503773A/ja
Publication of WO1995011243A1 publication Critical patent/WO1995011243A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the group R can also be an optionally substituted phenyl group, in particular a phenyl group disubstituted by Ci.galkyl and an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur.
  • Preferred 5 to 7-membered heterocyclic rings include those listed above.
  • Preferred substituents for such rings include Ci.galkyl, in particular methyl.
  • R 3 is as defined in formula (I) and Hal is halogen, or
  • the present invention also provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment of the aforementioned disorders.
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • Benzodioxan-5-carboxylic acid (prepared as described by E.A.Watts, in Azabicycloalkylbenzamides and pharmaceutical compositions containing them, EP 82-303057 June 1982) (15 g) was dissolved in a mixture of glacial acetic acid (67 ml) and acetic anhydride (67 ml). The solution was heated to 40° C and treated with a solution of fuming nitric acid (13 ml) in acetic acid (13 ml) at a rate such that the temperature was maintained at 45-50° C with occasional ice/water cooling. The mixture was stirred at 50°-53° C for 2 days, then cooled and filtered to give the title compound as a white powder (4.09 g, 22%).

Abstract

Dérivés d'amides représentés par la formule (I) ou sel desdits dérivés, dans laquelle R1 représente halogène, cyclaolkyle C¿3-6?, phényle éventuellement substitué ou un noyau hétérocyclique à 5-7 constituants éventuellement substitué et contenant de 1 à 3 hétéroatomes sélectionnés à partir d'oxygène, azote ou soufre; R?2¿ représente hydrogène, halogène, alkyle C¿1-6? alkoxy C1-6, acyle, nitro, trifluorométhyle ou cyano; R?3¿ représente hydrogène ou alkyle C¿1-6?; A représente -(CR?4R5)¿m- ou -O(CR4R5)n- oú R4 et R5 représentent indépendamment hydrogène ou alkyle C¿1-6?, m est 2 ou 3; n est 1, 2 ou 3 et B représente CONH ou NHCO. L'invention concerne également des procédés de préparation desdits dérivés, ainsi que des compositions pharmaceutiques contenant lesdits dérivés.
PCT/EP1994/003387 1993-10-19 1994-10-13 Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d WO1995011243A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP94930171A EP0724580A1 (fr) 1993-10-19 1994-10-13 Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d
JP7511300A JPH09503773A (ja) 1993-10-19 1994-10-13 ５ｈｔ−１ｄレセプター拮抗剤用のベンズアニリド誘導体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB939321490A GB9321490D0 (en) 1993-10-19 1993-10-19 Novel compounds
GB939325866A GB9325866D0 (en) 1993-12-17 1993-12-17 Novel compounds
GB9321490.6 1993-12-17
GB9325866.3 1993-12-17

Publications (1)

Publication Number Publication Date
WO1995011243A1 true WO1995011243A1 (fr) 1995-04-27

Family

ID=26303698

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/003387 WO1995011243A1 (fr) 1993-10-19 1994-10-13 Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d

Country Status (3)

Country Link
EP (1) EP0724580A1 (fr)
JP (1) JPH09503773A (fr)
WO (1) WO1995011243A1 (fr)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027058A2 (fr) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Nouveaux composes
WO1998027081A1 (fr) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Derives de sulfamide, procede de preparation de ces derives et utilisation de ces derniers en tant que medicaments
US6107328A (en) * 1995-09-18 2000-08-22 Smithkline Beecham P.L.C. Use of 5HT1B receptor antagonist for the treatment of vascular disease
US6124283A (en) * 1996-03-22 2000-09-26 Astra Aktiebolag Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO2001009123A1 (fr) * 1999-07-29 2001-02-08 Eli Lilly And Company Agonistes de la serotonine benzofurylpiperazine
WO2001009111A1 (fr) * 1999-07-29 2001-02-08 Eli Lilly And Company Benzofurylpiperazines et benzofurylhomopiperazines: antagonistes de la serotonine
US6291458B1 (en) 1997-07-02 2001-09-18 Astrazeneca Ab Morpholinobenzamide salts
US6313118B1 (en) 1997-07-25 2001-11-06 Astra Aktiebolag Substituted 1,2,3,4-tetrahydronaphthalene derivatives
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
US7041280B2 (en) 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
WO2006062481A1 (fr) * 2004-12-09 2006-06-15 Biovitrum Ab Nouveaux derives de benzofurane et leur utilisation dans le traitement de l'obesite, du diabete de type 2 et des troubles du systeme nerveux central
US7125898B2 (en) 2002-02-12 2006-10-24 Smithkline Beecham Corporation Nicotinamide derivatives useful as p38 inhibitors.
US7151118B2 (en) 2001-10-17 2006-12-19 Glaxo Group Limited Biphenylcarboxylic amide derivatives as p38-kinase inhibitors
US7166623B2 (en) 2001-10-17 2007-01-23 Glaxo Group Limited 2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
US7166597B2 (en) 2000-08-22 2007-01-23 Glaxo Group Limited Fused pyrazole derivatives being protein kinase inhibitors
US7183297B2 (en) 2001-10-17 2007-02-27 Glaxo Group Limited Biphenyl-derivatives as p38-kinase inhibitors
US7208629B2 (en) 2001-10-17 2007-04-24 Glaxo Group Limited 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
US7271289B2 (en) 2003-04-09 2007-09-18 Smithkline Beecham Corporation Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
US7384963B2 (en) 2001-10-17 2008-06-10 Glaxo Group Limited 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase
US7396843B2 (en) 2001-10-17 2008-07-08 Glaxo Group Limited 5′-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
US7432289B2 (en) 2001-10-17 2008-10-07 Glaxo Group Limited 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors
US7504395B2 (en) 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US7572790B2 (en) 2003-04-09 2009-08-11 Smithkline Beecham Corporation Biphenyl carboxylic amide p38 kinase inhibitors
US7626055B2 (en) 2003-04-09 2009-12-01 Smithkline Beecham Corporation Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors
US7642276B2 (en) 2002-07-31 2010-01-05 Smithkline Beecham Corporation Fused heteroaryl derivatives for use as P38 kinase inhibitors
US7838540B2 (en) 2003-08-11 2010-11-23 Glaxosmithkline Llc 3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors
WO2011098776A1 (fr) 2010-02-15 2011-08-18 Cambridge Enterprise Limited Modulateurs du récepteur de la 5-ht
US8445686B2 (en) * 2007-08-27 2013-05-21 Abbvie Inc. 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
WO2016028971A1 (fr) * 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Dérivés rattachés de benzamide utilisés comme puissants inhibiteurs de rock
WO2020183011A1 (fr) 2019-03-14 2020-09-17 Institut Curie Inhibiteurs de htr1d et leurs utilisations dans le traitement du cancer
US11498903B2 (en) 2017-08-17 2022-11-15 Bristol-Myers Squibb Company 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533266A1 (fr) * 1991-09-18 1993-03-24 Glaxo Group Limited Dérivés de benzanilide comme 5-HT1D antagonistes
EP0533268A1 (fr) * 1991-09-18 1993-03-24 Glaxo Group Limited Dérivés de benzanilide comme 5-HT1D antagonistes
EP0533267A1 (fr) * 1991-09-18 1993-03-24 Glaxo Group Limited Dérivés de benzanilide comme 5-HT1D antagonistes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533266A1 (fr) * 1991-09-18 1993-03-24 Glaxo Group Limited Dérivés de benzanilide comme 5-HT1D antagonistes
EP0533268A1 (fr) * 1991-09-18 1993-03-24 Glaxo Group Limited Dérivés de benzanilide comme 5-HT1D antagonistes
EP0533267A1 (fr) * 1991-09-18 1993-03-24 Glaxo Group Limited Dérivés de benzanilide comme 5-HT1D antagonistes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B.J. VAN STEEN ET AL.: "Structure-affinity relationship studies on 5-HT1A receptor ligands. Heterobicyclic phenylpiperazines with N4-aralkyl substituents.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 17, 19 August 1994 (1994-08-19), WASHINGTON US, pages 2761 - 2773 *
J.W. CLITHEROW ET AL.: "Evolution of a novel series of ((N,N-Dimethylamino)propyl)- and piperazinylbenzanilides as the first selective 5-HT1D antagonists.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 15, 22 July 1994 (1994-07-22), WASHINGTON US, pages 2253 - 2257 *

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107328A (en) * 1995-09-18 2000-08-22 Smithkline Beecham P.L.C. Use of 5HT1B receptor antagonist for the treatment of vascular disease
US6410530B1 (en) 1996-03-22 2002-06-25 Astrazeneca Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
US6124283A (en) * 1996-03-22 2000-09-26 Astra Aktiebolag Substituted 1,2,3,4-tetrahydronaphthalene derivatives
US6599904B2 (en) 1996-12-19 2003-07-29 Smithkline Beecham P.L.C. Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO1998027058A3 (fr) * 1996-12-19 1998-08-20 Smithkline Beecham Plc Nouveaux composes
WO1998027058A2 (fr) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Nouveaux composes
EA002351B1 (ru) * 1996-12-19 2002-04-25 Смитклайн Бичам Плс Производные сульфонамида, способ их получения и их использование в качестве лекарственных средств
WO1998027081A1 (fr) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Derives de sulfamide, procede de preparation de ces derives et utilisation de ces derniers en tant que medicaments
US6423717B1 (en) 1996-12-19 2002-07-23 Smithkline Beecham P.L.C. Sulphonamide derivatives, process for their preparation, and their use as medicaments
US6291458B1 (en) 1997-07-02 2001-09-18 Astrazeneca Ab Morpholinobenzamide salts
US6534652B2 (en) 1997-07-25 2003-03-18 Astrazeneca Ab Intermediates for the preparation of substituted 1,2,3,4-tetrahydronaphthalene derivatives
US6313118B1 (en) 1997-07-25 2001-11-06 Astra Aktiebolag Substituted 1,2,3,4-tetrahydronaphthalene derivatives
US6410532B2 (en) 1997-07-25 2002-06-25 Astrazeneca Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO2001009111A1 (fr) * 1999-07-29 2001-02-08 Eli Lilly And Company Benzofurylpiperazines et benzofurylhomopiperazines: antagonistes de la serotonine
US6638936B1 (en) 1999-07-29 2003-10-28 Eli Lilly And Company Benzofurylpiperazine serotonin agonists
US6967201B1 (en) 1999-07-29 2005-11-22 Eli Lilly And Company Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
WO2001009123A1 (fr) * 1999-07-29 2001-02-08 Eli Lilly And Company Agonistes de la serotonine benzofurylpiperazine
US7166597B2 (en) 2000-08-22 2007-01-23 Glaxo Group Limited Fused pyrazole derivatives being protein kinase inhibitors
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
US7041280B2 (en) 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US7049304B2 (en) 2001-06-29 2006-05-23 Genzyme Corporation Aryl boronic acids for treating obesity
US7456156B2 (en) 2001-06-29 2008-11-25 Genzyme Corporation Aryl boronic acids for treating obesity
US7557109B2 (en) 2001-07-20 2009-07-07 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US7504395B2 (en) 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US7166623B2 (en) 2001-10-17 2007-01-23 Glaxo Group Limited 2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
US7183297B2 (en) 2001-10-17 2007-02-27 Glaxo Group Limited Biphenyl-derivatives as p38-kinase inhibitors
US7208629B2 (en) 2001-10-17 2007-04-24 Glaxo Group Limited 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
US7309800B2 (en) 2001-10-17 2007-12-18 Glaxo Group Limited Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
US7384963B2 (en) 2001-10-17 2008-06-10 Glaxo Group Limited 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase
US7396843B2 (en) 2001-10-17 2008-07-08 Glaxo Group Limited 5′-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
US7432289B2 (en) 2001-10-17 2008-10-07 Glaxo Group Limited 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors
US7151118B2 (en) 2001-10-17 2006-12-19 Glaxo Group Limited Biphenylcarboxylic amide derivatives as p38-kinase inhibitors
US7709506B2 (en) 2002-02-12 2010-05-04 Glaxosmithkline Llc Nicotinamide derivatives useful as p38 inhibitors
US7125898B2 (en) 2002-02-12 2006-10-24 Smithkline Beecham Corporation Nicotinamide derivatives useful as p38 inhibitors.
US7514456B2 (en) 2002-02-12 2009-04-07 Smithkline Beecham Corporation Nicotinamide derivatives useful as p38 inhibitors
US7642276B2 (en) 2002-07-31 2010-01-05 Smithkline Beecham Corporation Fused heteroaryl derivatives for use as P38 kinase inhibitors
US7626055B2 (en) 2003-04-09 2009-12-01 Smithkline Beecham Corporation Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors
US7572790B2 (en) 2003-04-09 2009-08-11 Smithkline Beecham Corporation Biphenyl carboxylic amide p38 kinase inhibitors
US7271289B2 (en) 2003-04-09 2007-09-18 Smithkline Beecham Corporation Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
US7838540B2 (en) 2003-08-11 2010-11-23 Glaxosmithkline Llc 3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors
WO2006062481A1 (fr) * 2004-12-09 2006-06-15 Biovitrum Ab Nouveaux derives de benzofurane et leur utilisation dans le traitement de l'obesite, du diabete de type 2 et des troubles du systeme nerveux central
US20130310378A1 (en) * 2007-08-27 2013-11-21 Abbvie Inc. 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
US8445686B2 (en) * 2007-08-27 2013-05-21 Abbvie Inc. 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
US8895749B2 (en) 2007-08-27 2014-11-25 Abbvie Inc. 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
WO2011098776A1 (fr) 2010-02-15 2011-08-18 Cambridge Enterprise Limited Modulateurs du récepteur de la 5-ht
WO2016028971A1 (fr) * 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Dérivés rattachés de benzamide utilisés comme puissants inhibiteurs de rock
CN107108581A (zh) * 2014-08-21 2017-08-29 百时美施贵宝公司 作为强效rock抑制剂的回接苯甲酰胺衍生物
US10112939B2 (en) 2014-08-21 2018-10-30 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
US11498903B2 (en) 2017-08-17 2022-11-15 Bristol-Myers Squibb Company 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases
WO2020183011A1 (fr) 2019-03-14 2020-09-17 Institut Curie Inhibiteurs de htr1d et leurs utilisations dans le traitement du cancer

Also Published As

Publication number Publication date
EP0724580A1 (fr) 1996-08-07
JPH09503773A (ja) 1997-04-15

Similar Documents

Publication Publication Date Title
EP0724580A1 (fr) Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d
US5905080A (en) Amide and urea derivatives as 5HT1D receptor antagonists
EP0736025B1 (fr) Carboxamides de dihydrobenzofuranyle-biphenyle presentant une activite antagoniste du 5ht1d
US5756496A (en) Amide derivatives having 5HT1D-antagonist activity
US5935951A (en) 1-acyl-4-aliphatylaminopiperidine compounds
US5834471A (en) Amide derivatives as 5HT1D receptor antagonists
US5696122A (en) Indole and indoline derivatives as 5HT1D receptor antagonists
JP3262333B2 (ja) ５−ｈｔ１ａ拮抗物質としてのピペラジン誘導体
IL155875A (en) Piperazinylpirazine compounds as serotonin HT2 - 5 receptor agonists
HU191643B (en) Process for preparing new n-phenyl-n'-cycloalkyl-alkanoyl-piperazine derivatives
SK287912B6 (sk) 4-Phenylpyridine derivates, process for preparing thereof, pharmaceutically acceptable composition and use of the compound for the manufacture of medicaments
SK1142003A3 (en) Carboxamide compounds and their use as antagonists of a human 11CBY receptor
WO1998047868A1 (fr) Derives d'uree contenant un heterocycle utilises comme antagonistes des recepteurs 5ht1a, 5ht1b et 5ht¿1d?
US5972937A (en) Heterocyclic compounds possessing 5HT2C receptor antagonist activity
JP2009544579A (ja) 置換ベンジルアミン化合物
WO1995006644A1 (fr) Derives d'amide en tant qu'antagonistes du recepteur de 5ht1d
KR20050095601A (ko) 소디움/칼슘 교환시스템 억제에 유용한 피리딘 유도체들
KR20050119194A (ko) 정신병 및 신경 장애의 치료시 ５-ｈｔ 수용체 길항제로서사용하기 위한 １,３,４-치환된 피라졸
US5952325A (en) Tricyclic spiro compounds process for their preparation and their use of 5HT1D receptor antagonists
US5889022A (en) Indole, indoline and quinoline derivatives with 5HT1D (anti-depressive) activity
JP2009542707A (ja) ブチルおよびブチニルベンジルアミン化合物
JP2000506877A (ja) アザスピロ誘導体
US6066644A (en) Azaspiro derivatives with 5HT1B activity
US5298503A (en) N-(isoquinolin-5-ylsulphonyl) azacycloalkanes
WO1998050343A2 (fr) Derives (hetero)aryle carboxamides, leur procede de preparation et leur utilisation dans les desordres cns

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994930171

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1996 633787

Date of ref document: 19960516

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1994930171

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994930171

Country of ref document: EP